BioCardia Announces Pricing of Up To $12 Million Public Offering

$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock and short-term warrants to purchase ...